ARTICLE SUMMARY:
COVID didn’t put a damper on the VC’s ability to close its fourth and largest fund, targeting transformative healthcare technologies.
In late March and early April, as COVID-19 ravaged California and much of the Northeast, concerns were raised in venture circles that the pandemic would have devastating effects on medtech investing in particular. As healthcare systems were overwhelmed caring for the high volume of patients, start-ups and their investors worried about a twin impact: a dramatic falloff in elective procedures and a shutdown of clinical trials. Six months later if there were any lingering concerns, the close of a new fund by Longitude Capital arguably puts most, if not all, of those concerns to rest.
